<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tegaserod</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01079</strong>&#160; (APRD00096)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>investigational, withdrawn</td></tr><tr><th>Description</th><td><p>Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. On March 30, 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves. The <span class="caps">FDA</span> alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01079/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01079/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01079.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01079.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01079.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01079.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01079.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01079">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Tegaserod maleate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Zelmac</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zelnorm</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/serotonin-receptor-agonists">Serotonin Receptor Agonists</a></li></ul></td></tr><tr><th>CAS number</th><td>189188-57-6</td></tr><tr><th>Weight</th><td>Average: 301.3867<br>Monoisotopic: 301.190260383</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>23</sub>N<sub>5</sub>O</td></tr><tr><th>InChI Key</th><td>URPUECXJHQGUDU-JLHYYAGUSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H23N5O/c1-2-3-4-7-18-16(17)21-20-10-13-9-19-15-6-5-12(11-22)8-14(13)15/h5-6,8-10,20,22H,2-4,7,11H2,1H3,(H3,17,18,21)/b13-10+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(E)-1-({[(3Z)-5-(hydroxymethyl)-3H-indol-3-ylidene]methyl}amino)-2-pentylguanidine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCC\N=C(/N)NN\C=C1/C=NC2=C1C=C(CO)C=C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Indoles and Derivatives</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Indoles and Derivatives</td></tr><tr><th>Alternative parents</th><td>Benzene and Substituted Derivatives; Guanidines; Polyamines; Primary Alcohols; Amidines; Hydrazines and Derivatives</td></tr><tr><th>Substituents</th><td>benzene; guanidine; polyamine; amidine; primary alcohol; amine; hydrazine derivative; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the indoles and derivatives. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene  to form 2,3-benzopyrrole.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Provides relief from the symptoms of irritable bowel syndrome including chronic idiopathic constipation.</td></tr><tr><th>Pharmacodynamics</th><td>Tegaserod is indicated for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation. Irritable bowel syndrome with constipation and chronic idiopathic constipation are both lower gastrointestinal dysmotility disorders. Clinical investigations have shown that both motor and sensory functions of the gut appear to be altered in patients suffering from irritable bowel syndrome (IBS), while in patients with chronic idiopathic constipation, reduced intestinal motility is the predominant cause of the condition. Both the enteric nervous system, which acts to integrate and process information in the gut, and 5-hydroxytryptamine (5-HT, serotonin) are thought to represent key elements in the etiology of both IBS and idiopathic constipation. Approximately 95% of serotonin is found throughout the gastrointestinal tract, primarily stored in enterochromaffin cells but also in enteric nerves acting as a neurotransmitter. Serotonin has been shown to be involved in regulating motility, visceral sensitivity and intestinal secretion. Investigations suggest an important role of serotonin Type-4 (5-HT<sub>4</sub>) receptors in the maintenance of gastrointestinal functions in humans. 5-HT<sub>4</sub> receptor mRNA has been found throughout the human gastrointestinal tract.</td></tr><tr><th>Mechanism of action</th><td>Tegaserod is a 5-HT<sub>4</sub> receptor partial agonist that binds with high affinity at human 5-HT<sub>4</sub> receptors, whereas it has no appreciable affinity for 5-HT<sub>3</sub> or dopamine receptors. It has moderate affinity for 5-HT<sub>1</sub> receptors. Tegaserod, by acting as an agonist at neuronal 5-HT<sub>4</sub> receptors, triggers the release of further neurotransmitters such as calcitonin gene-related peptide from sensory neurons. The activation of 5-HT<sub>4</sub> receptors in the gastrointestinal tract stimulates the peristaltic reflex and intestinal secretion, as well as inhibits visceral sensitivity.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed after oral administration, with an absolute bioavailability of approximately 10%.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>368 &#177; 223 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>98%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Tegaserod is metabolized mainly via two pathways. The first is a presystemic acid catalyzed hydrolysis in the stomach followed by oxidation and conjugation which produces the main metabolite of tegaserod, 5-methoxyindole-3-carboxylic acid glucuronide. The main metabolite has negligible affinity for 5-HT<sub>4</sub> receptors in vitro. The second metabolic pathway of tegaserod is direct glucuronidation which leads to generation of three isomeric N-glucuronides.</p></td></tr><tr><th>Route of elimination</th><td>Approximately two-thirds of the orally administered dose of tegaserod is excreted unchanged in the feces, with the remaining one-third excreted in the urine, primarily as the main metabolite.</td></tr><tr><th>Half life</th><td>11 &#177; 5 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>77 +/- 15 L/h [IV administration]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Oral LD<sub>50</sub> in rat is 2000 mg/kg.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9973</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7842</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5939</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.921</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8978</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.959</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5488</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8522</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.5492</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6565</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.53</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7096</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7807</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6372</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8954</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7654</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5434
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7783
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9972
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6038 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.5123
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8334
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novartis pharmaceuticals corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td>Searched, but no interactions found.</td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>